In summary, Figure 2 and Figure 3 show that an AChE inhibitor with an irreversible mechanism of action given repeatedly over a period of time, similar to a clinical protocol in AD treatment [126], can produce a level of AChE inhibition that is at least double the inadequate 25–35% CNS AChE inhibition observed with the short-acting inhibitors [82,83,84,85,86]. This evidence concerns the gene ACHE and Alzheimer disease.